Why Cellaria

Cellaria creates high quality, next generation in vitro disease models that reflect the unique nature of a patient’s biology. All of our models begin with tissue from a patient, capturing clinically relevant details that inform model characterization. For cancer, Cellaria’s cell models capture novel cell populations from difficult-to-culture tumors.

For RNA-mediated iPS cell line derivation, Cellaria’s cell models enable interrogation of disease-specific mechanisms of action. Cellaria’s innovative products and services help lead the research community to more personalized therapeutics, revolutionizing and accelerating the search for a cure.

Cellaria Cancer Services

Cellaria works closely with cancer researchers to understand their unique and pressing challenges. These investigators face an uphill battle in bringing life-saving drugs to market—a process that can cost billions of dollars and take up to 10 years. However, the established testing models in use have limited relevance. To accelerate new progress in cancer research, scientists seek a new type of testing model; one that reflects the complexity of cancer and the unique needs of each patient.

Cancer researchers and scientists continue to rely on current cell lines, patient-derived xenografts (PDX), and mouse models as part of their testing methods. However, each of these long-used models has its limitations and drawbacks.

Current Cancer Drug Discover Tools

Current Cancer Drug Discovery Tools

Where established testing methods fall short, Cellaria fills the gap with our patient-derived cancer cell models and our custom cancer cell model development services.

WATCH OUR VIDEO about how Cellaria fills the gap that exists from the limitations and setbacks of current research methods.

Our customers use our (cell) models because they represent a diversity of the disease that has been unattainable to date. It allows drug and cancer researchers to make better decisions about which populations of patients are more likely to respond effectively to drugs that are under investigation.

David Deems, CEO

iPSC Reprogramming and Differentiation Services

At Cellaria, we empower your research and data relevancy by sourcing and reprogramming Induced Pluripotent Stem cells (iPS) from a specific patient clinical profile.

Our pipeline is built to meet the customer’s project and assay-specific requirements for cellular characteristics and functionality. The scalability of our iPS cells range from one million to one billion cells and can be delivered on a predictable schedule. Ultimately, this results in a significant reduction in costs and time to delivery.

These tissue-specific cell models are used for a wide range of applications, including the study of biological pathways, drug screening and development, and investigating pharmacological and toxicological mechanisms of action. Cellaria’s innovative models expand the available platforms on which researchers can build the next generation of personalized therapies.

Connect With Us

Learn more about how Cellaria can help transform your research efficacy.

Speak to a scientist or have a general inquiry

To help us better serve you, please provide a few more pieces of information:

Subscribe to Cellaria emails

Get the latest news on Cellaria's products, services, and events.

To help us better serve you, please provide a few more pieces of information: